--- title: "Weekly Recap | SPDR S&P Biotech +0.33%, mixed tape within biotech" type: "News" locale: "en" url: "https://longbridge.com/en/news/299515632.md" description: "SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20." datetime: "2026-09-19T07:01:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299515632.md) - [en](https://longbridge.com/en/news/299515632.md) - [zh-HK](https://longbridge.com/zh-HK/news/299515632.md) generator: "portal-rs" --- # Weekly Recap | SPDR S&P Biotech +0.33%, mixed tape within biotech ## The Week SPDR S&P Biotech (XBI) rose 0.33% this week to close at $156.72, while the S&P 500 fell 0.08%, leaving XBI about 0.41 percentage points ahead of the benchmark. The week was choppy, with an intraweek range of 4.99%. The ETF started Monday by edging up to $157.60, pulled back to $154.03 on Tuesday, touched a weekly low of $152.50 on Wednesday, then rebounded to a weekly high of $160.33 on Thursday before easing to $156.72 on Friday. The close was slightly above the prior week’s $156.20. ## Key Events The biotech complex was driven by a handful of names that matter to XBI’s passive basket. Moderna gained after Phase III melanoma success, and some call options jumped 381% in a single day. Natera reported a lung cancer MRD study linking Signatera results to three-year recurrence-free survival in 1,129 patients, and the stock rose 12.3% on the week. Twist Bioscience climbed 31.26% after a tie-up with Lilly’s TuneLab on AI-driven drug discovery, though BWS Financial kept a sell rating with a $45 target. Halozyme swung on plans for a $1.3 billion convertible bond offering, then hit a record high after pricing. Iovance Biotherapeutics was up 307% for the year, and Roivant Sciences wrapped up its annual meeting with governance approvals. The common thread was cancer diagnostics, vaccines and AI-enabled drug development. ## The Week Ahead No XBI constituents report earnings next week, and the macro calendar is light. Tuesday brings the Richmond Fed manufacturing index, with a prior reading of 4. Thursday includes jobless claims, the current account balance and new home sales, with the annualised rate expected at 608,000 versus 607,000 prior. Any shift in rate-related sentiment could ripple into growth-sensitive assets. ## In Short XBI eked out a weekly gain and outperformed the S&P 500, but the tape was two-sided. Cancer vaccines, liquid biopsy and AI-driven drug discovery drew attention, while Halozyme’s convertible issuance stirred volatility. The latest-session money flow snapshot shows small-lot money as a net buyer by a wide margin. With the 60-day range spanning $143.775 to $169.89, XBI sits near the middle of that band at $156.72. The next test is how macro data affects rate expectations and whether the week’s pipeline themes hold up. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ## Related News & Research - [Michael Saylor Says, 'A Little More Orange': Will Strategy Report BTC Purchases After Hitting Pause for 3 Weeks?](https://longbridge.com/en/news/299601303.md) - [BREAKINGVIEWS-Deutsche Telekom's best M&A path may be in EU](https://longbridge.com/en/news/299614100.md) - [Ares Management (ARES) Forms Logistics Venture, Is The Stock A Bargain?](https://longbridge.com/en/news/299564323.md) - [PRESS DIGEST-Financial Times - September 21](https://longbridge.com/en/news/299570837.md) - [Trafigura launches Volare tanker arm, plans Oslo listing](https://longbridge.com/en/news/299599998.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**